Literature DB >> 26565916

FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer.

Bingchen Han1, Ying Qu1, Yanli Jin1, Yi Yu1, Nan Deng2, Kolja Wawrowsky3, Xiao Zhang2, Na Li4, Shikha Bose5, Qiang Wang6, Sugunadevi Sakkiah7, Ravinder Abrol7, Tor W Jensen8, Benjamin P Berman6, Hisashi Tanaka1, Jeffrey Johnson1, Bowen Gao1, Jijun Hao9, Zhenqiu Liu2, Ralph Buttyan10, Partha S Ray8, Mien-Chie Hung11, Armando E Giuliano1, Xiaojiang Cui12.   

Abstract

The mesoderm- and epithelial-mesenchymal transition-associated transcription factor FOXC1 is specifically overexpressed in basal-like breast cancer (BLBC), but its biochemical function is not understood. Here, we demonstrate that FOXC1 controls cancer stem cell (CSC) properties enriched in BLBC cells via activation of Smoothened (SMO)-independent Hedgehog (Hh) signaling. This non-canonical activation of Hh is specifically mediated by Gli2. Furthermore, we show that the N-terminal domain of FOXC1 (aa 1-68) binds directly to an internal region (aa 898-1168) of Gli2, enhancing the DNA-binding and transcription-activating capacity of Gli2. FOXC1 expression correlates with that of Gli2 and its targets in human breast cancers. Moreover, FOXC1 overexpression reduces sensitivity to anti-Hedgehog (Hh) inhibitors in BLBC cells and xenograft tumors. Together, these findings reveal FOXC1-mediated non-canonical Hh signaling that determines the BLBC stem-like phenotype and anti-Hh sensitivity, supporting inhibition of FOXC1 pathways as potential approaches for improving BLBC treatment.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26565916      PMCID: PMC4806384          DOI: 10.1016/j.celrep.2015.09.063

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  47 in total

Review 1.  Control of stem cells and cancer stem cells by Hedgehog signaling: pharmacologic clues from pathway dissection.

Authors:  Sonia Coni; Paola Infante; Alberto Gulino
Journal:  Biochem Pharmacol       Date:  2012-11-10       Impact factor: 5.858

2.  Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation.

Authors:  Yoshiki Omatsu; Masanari Seike; Tatsuki Sugiyama; Tsutomu Kume; Takashi Nagasawa
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

3.  Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Authors:  James Kim; Blake T Aftab; Jean Y Tang; Daniel Kim; Alex H Lee; Melika Rezaee; Jynho Kim; Baozhi Chen; Emily M King; Alexandra Borodovsky; Gregory J Riggins; Ervin H Epstein; Philip A Beachy; Charles M Rudin
Journal:  Cancer Cell       Date:  2013-01-03       Impact factor: 31.743

4.  Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.

Authors:  Na Li; Mengqian Chen; Sarah Truong; Chunhong Yan; Ralph Buttyan
Journal:  Prostate       Date:  2014-08-11       Impact factor: 4.104

5.  A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.

Authors:  Stanley B Kaye; Louis Fehrenbacher; Robert Holloway; Amnon Amit; Beth Karlan; Brian Slomovitz; Paul Sabbatini; Ling Fu; Robert L Yauch; Ilsung Chang; Josina C Reddy
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

6.  FOXC1 is enriched in the mammary luminal progenitor population, but is not necessary for mouse mammary ductal morphogenesis.

Authors:  Gina M Sizemore; Steven T Sizemore; Bhupinder Pal; Christine N Booth; Darcie D Seachrist; Fadi W Abdul-Karim; Tsutomu Kume; Ruth A Keri
Journal:  Biol Reprod       Date:  2013-07-11       Impact factor: 4.285

7.  FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.

Authors:  Brett G Hollier; Agata A Tinnirello; Steven J Werden; Kurt W Evans; Joseph H Taube; Tapasree Roy Sarkar; Nathalie Sphyris; Maryam Shariati; Sreedevi V Kumar; Venkata L Battula; Jason I Herschkowitz; Rudy Guerra; Jeffrey T Chang; Naoyuki Miura; Jeffrey M Rosen; Sendurai A Mani
Journal:  Cancer Res       Date:  2013-02-01       Impact factor: 12.701

8.  Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma.

Authors:  Limin Xia; Wenjie Huang; Dean Tian; Hongwu Zhu; Xingshun Qi; Zheng Chen; Yongguo Zhang; Hao Hu; Daiming Fan; Yongzhan Nie; Kaichun Wu
Journal:  Hepatology       Date:  2013-02       Impact factor: 17.425

9.  High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.

Authors:  Long-Xiao Wei; Run-Suo Zhou; Hai-Feng Xu; Jun-Yan Wang; Meng-Hui Yuan
Journal:  Tumour Biol       Date:  2012-12-22

10.  Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.

Authors:  Marketa Zvelebil; Erik Oliemuller; Qiong Gao; Olivia Wansbury; Alan Mackay; Howard Kendrick; Matthew J Smalley; Jorge S Reis-Filho; Beatrice A Howard
Journal:  Breast Cancer Res       Date:  2013-03-18       Impact factor: 6.466

View more
  58 in total

1.  The transcription factor Foxc1a in zebrafish directly regulates expression of nkx2.5, encoding a transcriptional regulator of cardiac progenitor cells.

Authors:  Yunyun Yue; Mingyang Jiang; Luqingqing He; Zhaojunjie Zhang; Qinxin Zhang; Chun Gu; Meijing Liu; Nan Li; Qingshun Zhao
Journal:  J Biol Chem       Date:  2017-11-21       Impact factor: 5.157

Review 2.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

Review 3.  Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells.

Authors:  Kirti S Prabhu; Afsheen Raza; Thasni Karedath; Syed Shadab Raza; Hamna Fathima; Eiman I Ahmed; Shilpa Kuttikrishnan; Lubna Therachiyil; Michal Kulinski; Said Dermime; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

4.  Tissue-inappropriate derepression of FOXC1 is frequent and functional in human acute myeloid leukemia.

Authors:  Tim D D Somerville; Tim C P Somervaille
Journal:  Mol Cell Oncol       Date:  2016-01-19

5.  FOXC1 promotes proliferation and epithelial-mesenchymal transition in cervical carcinoma through the PI3K-AKT signal pathway.

Authors:  Liu Huang; Zheng Huang; Yi Fan; Langchi He; Ming Ye; Kun Shi; Bing Ji; Jiezhen Huang; Yibin Wang; Qiufen Li
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 6.  Prognostic Significance of FOXC1 in Various Cancers: A Systematic Review and Meta-Analysis.

Authors:  Nadana Sabapathi; Shanthi Sabarimurugan; Madhav Madurantakam Royam; Chellan Kumarasamy; Xingzhi Xu; Gaixia Xu; Rama Jayaraj
Journal:  Mol Diagn Ther       Date:  2019-12       Impact factor: 4.074

7.  EMT programs promote basal mammary stem cell and tumor-initiating cell stemness by inducing primary ciliogenesis and Hedgehog signaling.

Authors:  Vincent J Guen; Tony E Chavarria; Cornelia Kröger; Xin Ye; Robert A Weinberg; Jacqueline A Lees
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-20       Impact factor: 11.205

Review 8.  Hedgehog signalling in liver pathophysiology.

Authors:  Mariana Verdelho Machado; Anna Mae Diehl
Journal:  J Hepatol       Date:  2017-10-26       Impact factor: 25.083

9.  FOXC1-induced Gli2 activation: A non-canonical pathway contributing to stemness and anti-Hedgehog resistance in basal-like breast cancer.

Authors:  Bingchen Han; Ying Qu; Yi Yu-Rice; Jeffrey Johnson; Xiaojiang Cui
Journal:  Mol Cell Oncol       Date:  2016-01-11

10.  A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth.

Authors:  Bingchen Han; Felix Alonso-Valenteen; Zhe Wang; Nan Deng; Tian-Yu Lee; Bowen Gao; Ying Zhang; Yali Xu; Xinfeng Zhang; Sandrine Billet; Xuemo Fan; Stephen Shiao; Neil Bhowmick; Lali Medina-Kauwe; Armando Giuliano; Xiaojiang Cui
Journal:  Mol Ther       Date:  2021-07-16       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.